Grass pollen allergoids - Allergopharma

Drug Profile

Grass pollen allergoids - Allergopharma

Alternative Names: Allergovit 6 Grasses

Latest Information Update: 08 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Allergopharma
  • Class Allergens; Antiallergics; Plant allergy immunotherapies
  • Mechanism of Action Immunosuppressants; T lymphocyte modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Grass pollen hypersensitivity
  • Phase III Rhinoconjunctivitis; Seasonal allergic rhinitis

Most Recent Events

  • 07 Aug 2017 Phase-II clinical trials in Rhinoconjunctivitis in Spain (SC) (EudraCT2017-000754-19)
  • 07 Aug 2017 Phase-II clinical trials in Seasonal allergic rhinitis in Spain (SC) (EudraCT2017-000754-19)
  • 19 Nov 2015 Phase-III clinical trials in Rhinoconjunctivitis (Prevention of relapse) in Germany (SC) (EudraCT2015-002409-13)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top